EU HTA – Achieving broad access fast! What will it take for innovative medicines to succeed?

Healthcare in Europe prepares for the EU HTA. Join our discussion on recent national reforms and essential policies to accelerate patient access to groundbreaking medicines. 

Anticipating the imminent launch of the joint clinical assessment (JCA) in January 2025, the healthcare industry in Europe is preparing for a transformative shift in how innovations are evaluated and approved. Considering the recent national reforms across Europe, our expert panel will comment on the evolving landscape.

Join us as we unravel the essential healthcare system requirements and policies crucial for accelerating patient access to groundbreaking medicines.

Of interest to:Pharmaceutical industry: Executives, managers, and professionals from pharmaceutical companies involved in drug development and market access strategies
Healthcare providers: Physicians, pharmacists, and other healthcare practitioners interested in understanding how the EU HTA will affect treatment options and patient care
Patient advocacy groups: Representatives from organizations that advocate for patient rights and access to innovative therapies
Healthcare policymakers: Government officials and legislators responsible for healthcare policy and regulation in European countries
Regulatory affairs: Individuals working in regulatory environments who need to stay informed about changes in HTA processes

Your details

By submitting this form you are agreeing to our Terms & Conditions and Privacy Policy, and agree to receiving relevant emails from The Evidence Base about the latest news and editorial features.

Terms & Conditions

I agree to receive third party emails to keep me informed of relevant products and services relevant to my industry.

I agree for my registration data to be transferred to the sponsoring organization (Cencora).

Subscribing to

Confirm sign-up

What you will learn:

Critical success factors for the EU HTA Regulation implementation
Strategies to leverage JCA reports while ensuring broad patient access across Europe
Recommendations for collaboration among member states, healthcare systems, and industry stakeholders
How the new JCA will impact healthcare delivery and innovation

Moderator:

Herbert Altmann
Vice President, Market Access & Healthcare Consulting Europe, Cencora

Herbert Altmann, PhD, is Vice President, Market Access & Healthcare Consulting Europe with PharmaLex, part of Cencora. He leads the European Market Access department, working with pharmaceutical companies bringing innovative medicines to patients with unmet medical need as fast as possible. Before joining PharmaLex, Herbert was Head Value & Access Region Europe, Novartis Pharma, leading the Market Access department to ensure access for patients to Novartis brands. He was the NVS representative on the EFPIA HTA working group, participating in two Joint Action 3 assessments.

Current speakers:

Iga Lipska
Chairwoman of the Board, Health Policy Institute Poland

Iga Lipska is a Medical Doctor with a Master of Science in public health, graduating from the University of Utrecht, where she earned her PhD in HTA of new medicines. She has extensive experience in healthcare, focusing on HTA, drug pricing, and public health. Iga significantly impacted HTA in Poland, aiding the establishment of the national HTA Agency and contributing to its implementation in Central Eastern Europe. She held various leadership roles, including Director of Drug Policy and Pharmacy at the Ministry of Health. Currently, she chairs the Board at the Health Policy Institute in Poland and oversees postgraduate education at the Academy of Applied Medical and Social Sciences.

François Meyer
Independent Consultant

François Meyer spent 10 years as a physician in the teaching hospitals of Montpellier, France, followed by 5 years in R&D for a Swiss pharmaceutical company. In 1997, he joined the French Medicines Agency as Deputy Director of the Drug Evaluation Department. In 2005, he was appointed Director of the HTA Department of the Haute Autorité de Santé (HAS) and, in 2011, Advisor to the President of the HAS for International Affairs. He was a member of the Board of Directors of HTAi and has played a leading role in European HTA cooperation since 2006. Since 2023, Dr Meyer has been an independent consultant and special advisor to the RWE4Decisions project coordinated by FIPRA, a Brussels-based public affairs agency.

Oriol Solà-Morales
CEO, Health Innovation Technology Transfer

Oriol is the CEO of HITT, a biotech consultancy specializing in Market Access and Technology Transfer. He has a robust career in planning, policy, and decision-making across micro-, meso-, and macro-policy areas. He previously served as CAHTA’s (Catalan Agency HTA) Director from 2007 to 2011 and held management positions at Sant Joan de Déu Hospital and Sagessa. In 2011, he founded HITT, which evolved into the HiTT Foundation in 2019 to promote sustainable healthcare innovations. An MD in Internal Medicine, Oriol holds an MSc from the London School of Economics and a PhD from Universitat Rovira i Virgili.

Share this webinar